Opinion

Video

Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.

  1. Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
  2. BCG‐unresponsiveness (definition?)
    1. Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
  3. Gene therapy: nadofaragene firadenovec
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
FDA approves expanded access program to provide alternative source of BCG
February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke
According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Anktiva under review in UK for BCG-unresponsive NMIBC with CIS
February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke
Anktiva is also currently under review for the CIS indication in the EU.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor
OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.
© 2025 MJH Life Sciences

All rights reserved.